• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Pharma
    • Oncology
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Supply Chain
    • AI and Machine Learning
  • Awards
    • Outsourcing Awards
    • Innovation Awards
    • AI Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Pharma
    • Oncology
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Supply Chain
    • AI and Machine Learning
  • Awards
    • Outsourcing Awards
    • Innovation Awards
    • AI Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Enhertu

Asia
Pharma

Enhertu successor, ESMO, Gilead—Fierce Pharma Asia

Fierce provides a deep dive into the hunt for the next Enhertu in breast cancer. ESMO 2026 data featured Chinese assets backed by Big Pharma.
Angus Liu Oct 30, 2026 8:45am
topic report
National Breast Cancer Awareness Month pink ribbon
Favicon Fierce Biotech

After Enhertu: The slow hunt for next-gen HER2 breast cancer drugs

Oct 28, 2026 9:00am
Asia

US' China deal policy, WCLC, Legend CEO—Fierce Pharma Asia

Sep 18, 2026 10:20am
football goalpost touchdown score

AZ, Daiichi's Enhertu nabs long-sought NHS blessing from NICE

Sep 16, 2026 7:30pm
Enhertu

Increased deaths shadow Enhertu’s first-line lung cancer data

Sep 13, 2026 7:00pm
AZ

AstraZeneca dual lung cancer wins softened by bispecific fail

Aug 17, 2026 10:56am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Biotech
    • Fierce Healthcare
    • Fierce Pharma
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings